{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cmax",
    "query": {
      "condition": "Cmax"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cmax&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T18:02:57.246Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01721070",
      "title": "Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Sufentanil NanoTab (SUF NT) 15 mcg",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Talphera, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 19,
      "start_date": "2012-11",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2016-11-04",
      "last_synced_at": "2026-07-22T18:02:57.246Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01721070"
    },
    {
      "nct_id": "NCT01392807",
      "title": "Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic; Functional Disturbance"
      ],
      "interventions": [
        {
          "name": "NKTR-118",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2011-07",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2014-10-15",
      "last_synced_at": "2026-07-22T18:02:57.246Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01392807"
    },
    {
      "nct_id": "NCT01365000",
      "title": "Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "NKTR118 Formulation 1",
          "type": "DRUG"
        },
        {
          "name": "NKTR118 Formulation 2",
          "type": "DRUG"
        },
        {
          "name": "NKTR118 Formulation 3",
          "type": "DRUG"
        },
        {
          "name": "NKTR118 Formulation 1a",
          "type": "DRUG"
        },
        {
          "name": "NKTR118 Formulation 3a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 21,
      "start_date": "2011-06",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2014-10-15",
      "last_synced_at": "2026-07-22T18:02:57.246Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01365000"
    },
    {
      "nct_id": "NCT02359045",
      "title": "Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relative Bioavailability",
        "AUC",
        "Cmax",
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "D1400147",
          "type": "DRUG"
        },
        {
          "name": "D14000136",
          "type": "DRUG"
        },
        {
          "name": "D14000137",
          "type": "DRUG"
        },
        {
          "name": "Epanova®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 137,
      "start_date": "2015-02-12",
      "completion_date": "2015-07-27",
      "has_results": true,
      "last_update_posted_date": "2017-05-01",
      "last_synced_at": "2026-07-22T18:02:57.246Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02359045"
    },
    {
      "nct_id": "NCT02112851",
      "title": "Processed Orange and the Glycemic Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Maximum Observed Plasma Glucose Concentration (Cmax)"
      ],
      "interventions": [
        {
          "name": "Orange flavored beverage",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "PepsiCo Global R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "30 Years to 65 Years · Male only"
      },
      "enrollment_count": 38,
      "start_date": "2014-03-07",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2021-03-10",
      "last_synced_at": "2026-07-22T18:02:57.246Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02112851"
    },
    {
      "nct_id": "NCT01921920",
      "title": "Prilosec Bioequivalence Study in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioequivalence, AUC, Cmax, Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 54,
      "start_date": "2013-08",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2013-11-25",
      "last_synced_at": "2026-07-22T18:02:57.246Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01921920"
    },
    {
      "nct_id": "NCT02041273",
      "title": "Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "palbociclib isethionate (phase 1 and 2 studies)",
          "type": "DRUG"
        },
        {
          "name": "palbociclib commercial free base capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2014-01",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-03-17",
      "last_synced_at": "2026-07-22T18:02:57.246Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02041273"
    },
    {
      "nct_id": "NCT06293365",
      "title": "Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sjögrens Disease",
        "Systemic Lupus Erythematosus",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "VAY736 1ml PFS",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VAY736 2 ml PFS",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VAY736 2ml AI",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 155,
      "start_date": "2024-07-02",
      "completion_date": "2029-01-16",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-07-22T18:02:57.246Z",
      "location_count": 17,
      "location_summary": "Anniston, Alabama • Fullerton, California • La Palma, California + 14 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Palma",
          "state": "California"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06293365"
    },
    {
      "nct_id": "NCT01906125",
      "title": "A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "palbociclib capsule: phase 1 and 2 studies",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib capsule: phase 3 studies",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib capsule: ICH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 73,
      "start_date": "2013-09",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2014-01-20",
      "last_synced_at": "2026-07-22T18:02:57.246Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01906125"
    },
    {
      "nct_id": "NCT01441869",
      "title": "Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin"
      ],
      "interventions": [
        {
          "name": "Onglyza (saxagliptin)",
          "type": "DRUG"
        },
        {
          "name": "Diabex",
          "type": "DRUG"
        },
        {
          "name": "5-mg saxagliptin/1000 mg metformin",
          "type": "DRUG"
        },
        {
          "name": "5-mg saxagliptin/500 mg metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2011-10",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2012-02-08",
      "last_synced_at": "2026-07-22T18:02:57.246Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01441869"
    }
  ]
}